Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of safety and immunogenicity of HNVAC, an MDCK-based H1N1 pandemic influenza vaccine, in Phase I single centre and Phase II/III multi-centre, double-blind, randomized, placebo-controlled, parallel assignment studies.
Basavaraj VH, Sampath G, Hegde NR, Mohan VK, Ella KM. Basavaraj VH, et al. Among authors: ella km. Vaccine. 2014 Jul 31;32(35):4592-4597. doi: 10.1016/j.vaccine.2014.05.039. Epub 2014 May 21. Vaccine. 2014. PMID: 24856782 Clinical Trial.
Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation.
Ganneru B, Jogdand H, Daram VK, Das D, Molugu NR, Prasad SD, Kannappa SV, Ella KM, Ravikrishnan R, Awasthi A, Jose J, Rao P, Kumar D, Ella R, Abraham P, Yadav PD, Sapkal GN, Shete-Aich A, Desphande G, Mohandas S, Basu A, Gupta N, Vadrevu KM. Ganneru B, et al. Among authors: ella km. iScience. 2021 Apr 23;24(4):102298. doi: 10.1016/j.isci.2021.102298. Epub 2021 Mar 10. iScience. 2021. PMID: 33723528 Free PMC article.
A Japanese Encephalitis Vaccine From India Induces Durable and Cross-protective Immunity Against Temporally and Spatially Wide-ranging Global Field Strains.
Singh A, Mitra M, Sampath G, Venugopal P, Rao JV, Krishnamurthy B, Gupta MK, Sri Krishna S, Sudhakar B, Rao NB, Kaushik Y, Gopinathan K, Hegde NR, Gore MM, Krishna Mohan V, Ella KM. Singh A, et al. Among authors: ella km. J Infect Dis. 2015 Sep 1;212(5):715-25. doi: 10.1093/infdis/jiv023. Epub 2015 Jan 18. J Infect Dis. 2015. PMID: 25601942 Clinical Trial.
Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model.
Mohandas S, Yadav PD, Shete-Aich A, Abraham P, Vadrevu KM, Sapkal G, Mote C, Nyayanit D, Gupta N, Srinivas VK, Kadam M, Kumar A, Majumdar T, Jain R, Deshpande G, Patil S, Sarkale P, Patil D, Ella R, Prasad SD, Sharma S, Ella KM, Panda S, Bhargava B. Mohandas S, et al. Among authors: ella km. iScience. 2021 Feb 19;24(2):102054. doi: 10.1016/j.isci.2021.102054. Epub 2021 Jan 9. iScience. 2021. PMID: 33521604 Free PMC article.
Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants.
Vadrevu KM, Ganneru B, Reddy S, Jogdand H, Raju D, Sapkal G, Yadav P, Reddy P, Verma S, Singh C, Redkar SV, Gillurkar CS, Kushwaha JS, Mohapatra S, Bhate A, Rai SK, Ella R, Abraham P, Prasad S, Ella K. Vadrevu KM, et al. Among authors: ella r, ella k. Sci Rep. 2022 Jul 14;12(1):12038. doi: 10.1038/s41598-022-16097-3. Sci Rep. 2022. PMID: 35835822 Free PMC article. Clinical Trial.
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.
Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, Das D, Raju D, Praturi U, Sapkal G, Yadav P, Reddy P, Verma S, Singh C, Redkar SV, Gillurkar CS, Kushwaha JS, Mohapatra S, Bhate A, Rai S, Panda S, Abraham P, Gupta N, Ella K, Bhargava B, Vadrevu KM. Ella R, et al. Among authors: ella k. Lancet Infect Dis. 2021 Jul;21(7):950-961. doi: 10.1016/S1473-3099(21)00070-0. Epub 2021 Mar 8. Lancet Infect Dis. 2021. PMID: 33705727 Free PMC article. Clinical Trial.
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.
Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, Aileni VK, Kanungo S, Rai S, Reddy P, Verma S, Singh C, Redkar S, Mohapatra S, Pandey A, Ranganadin P, Gumashta R, Multani M, Mohammad S, Bhatt P, Kumari L, Sapkal G, Gupta N, Abraham P, Panda S, Prasad S, Bhargava B, Ella K, Vadrevu KM; COVAXIN Study Group. Ella R, et al. Among authors: ella k. Lancet. 2021 Dec 11;398(10317):2173-2184. doi: 10.1016/S0140-6736(21)02000-6. Epub 2021 Nov 11. Lancet. 2021. PMID: 34774196 Free PMC article. Clinical Trial.
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.
Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, Ganneru B, Sapkal G, Yadav P, Abraham P, Panda S, Gupta N, Reddy P, Verma S, Kumar Rai S, Singh C, Redkar SV, Gillurkar CS, Kushwaha JS, Mohapatra S, Rao V, Guleria R, Ella K, Bhargava B. Ella R, et al. Among authors: ella k. Lancet Infect Dis. 2021 May;21(5):637-646. doi: 10.1016/S1473-3099(20)30942-7. Epub 2021 Jan 21. Lancet Infect Dis. 2021. PMID: 33485468 Free PMC article. Clinical Trial.
40 results